Drug
Ramosetron
Ramosetron: highest development phase Post-Market, developed by Astellas. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Astellas
Trials
| Drug | Phase | Indication |
|---|---|---|
| ramosetron, aprepitant, dexamethasone NCT02532634 | Post-Market | Cancer |
Latest
No recent events.
Follow Ramosetron on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.